Compare · CAH vs COSM
CAH vs COSM
Side-by-side comparison of Cardinal Health Inc. (CAH) and Cosmos Health Inc. (COSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and COSM operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH is the larger of the two at $58.75B, about 1735.4x COSM ($33.9M).
- Over the past year, CAH is up 62.4% and COSM is down 98.4% - CAH leads by 160.9 points.
- COSM has been more active in the news (7 items in the past 4 weeks vs 5 for CAH).
- CAH has more recent analyst coverage (25 ratings vs 0 for COSM).
- Company
- Cardinal Health Inc.
- Cosmos Health Inc.
- Price
- $254.13+0.17%
- $0.33-3.10%
- Market cap
- $58.75B
- $33.9M
- 1M return
- +12.23%
- +11.40%
- 1Y return
- +62.45%
- -98.42%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 0
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
Latest CAH
- Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
- Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
- SEC Form DEF 14A filed by Cardinal Health Inc.
- SEC Form DEFA14A filed by Cardinal Health Inc.
- Chief Accounting Officer Scherer Mary C. sold $546,473 worth of shares (2,302 units at $237.39), decreasing direct ownership by 45% to 2,811 units (SEC Form 4)
- Chief Executive Officer Hollar Jason M. sold $29,375,516 worth of shares (124,529 units at $235.89), decreasing direct ownership by 40% to 190,603 units (SEC Form 4)
- CEO, GMPD Segment Mason Stephen M sold $8,274,117 worth of shares (35,000 units at $236.40), decreasing direct ownership by 66% to 18,061 units (SEC Form 4)
- CEO, PSS Segment Weitzman Deborah sold $1,731,524 worth of shares (7,354 units at $235.45), decreasing direct ownership by 9% to 77,901 units (SEC Form 4)
- Chief Financial Officer Alt Aaron E sold $9,926,140 worth of shares (42,000 units at $236.34), decreasing direct ownership by 67% to 20,495 units (SEC Form 4)
Latest COSM
- Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
- Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
- SEC Form 8-K filed by Cosmos Health Inc.
- Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
- Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
- Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
- Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
- Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
- Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
- Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units